Personalized dosing of skin cancer drug aims to reduce side effects
NCT ID NCT05651828
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study compares four different dosing schedules of the drug vismodegib in people with advanced basal cell carcinoma. The goal is to see if personalized, intermittent dosing works as well as or better than standard continuous dosing while being easier to tolerate. About 34 adults with advanced skin cancer will take the drug at home and be monitored for how long the treatment works and how the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Vismodegib (Erivedge) oral capsule
- What this could lead to
- If successful, this could lead to a more tolerable and effective way to manage advanced basal cell carcinoma with fewer side effects.
- What could go wrong
- This is a very early phase 1 trial with only 34 participants, so results may not apply broadly. The personalized dosing schedules may not improve outcomes over standard dosing.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BASAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33617, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.